Clinical Scenario

This protocol applies to patients with advanced, non-resectable, non-irradiable or metastatic thymoma at Masaoka-Koga stage IVB — a setting where surgery and radiotherapy are no longer feasible and systemic chemotherapy is the principal treatment modality.

First-Line Treatment — Response Goals Not Achieved

The patient has already received a cisplatin-based multiagent combination chemotherapy regimen as definitive first-line treatment. Despite this, the goals of tumour shrinkage and relief of tumour-related symptoms — assessed by RECIST v1.1 criteria — were not reached, indicating progression or insufficient response and the need to escalate to the next treatment step.

Next Step: Second-Line Chemotherapy

After first-line failure, a second-line chemotherapy approach is indicated. This involves an alternative combination regimen, with several options and specific clinical considerations that determine which is most appropriate. The complete treatment algorithm, choice of regimen, and conditions for considering re-administration of a prior effective regimen are detailed in the structured protocol.

References

DOI: 10.1093/annonc/mdv277

Chemotherapy should be offered as single modality treatment in advanced, non-resectable, non-irradiable or metastatic (stage IVB) thymic epithelial tumours.
Preferred regimens for second-line treatment include carboplatin plus paclitaxel, and platin plus etoposide [III, B]; capecitabine plus gemcitabine is an option (Table 6) [III, B].
The re-administration of a previously effective regimen should be considered [IV, B], especially in case of previous response, late occurring recurrence and, for anthracyclines, a patient in a good medical condition who has not received cumulative doses precluding the safe delivery of at least three additional cycles.
Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 criteria should be used to assess response to chemotherapy [V, A].

View source ↗

What to Do When First-Line Chemotherapy Has Not Worked in Advanced Non-Resectable or Metastatic Thymoma (Masaoka-Koga Stage IVB)

References